127.59
Schlusskurs vom Vortag:
$124.38
Offen:
$124.02
24-Stunden-Volumen:
234.62K
Relative Volume:
0.29
Marktkapitalisierung:
$7.47B
Einnahmen:
$633.51M
Nettoeinkommen (Verlust:
$-8.10M
KGV:
-411.58
EPS:
-0.31
Netto-Cashflow:
$131.26M
1W Leistung:
+3.19%
1M Leistung:
+7.81%
6M Leistung:
-11.57%
1J Leistung:
+3.22%
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Vergleichen Sie RGEN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RGEN
Repligen Corp
|
127.77 | 7.47B | 633.51M | -8.10M | 131.26M | -0.31 |
![]()
ISRG
Intuitive Surgical Inc
|
533.64 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
176.85 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
88.90 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
RMD
Resmed Inc
|
256.76 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
222.05 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-29 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2025-03-18 | Eingeleitet | Evercore ISI | In-line |
2025-02-10 | Eingeleitet | TD Cowen | Buy |
2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-06-18 | Eingeleitet | Guggenheim | Neutral |
2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2022-07-20 | Eingeleitet | UBS | Buy |
2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
2019-11-15 | Eingeleitet | Stifel | Buy |
2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
2019-08-23 | Fortgesetzt | Stephens | Overweight |
2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2018-12-17 | Hochstufung | CL King | Neutral → Buy |
2018-11-12 | Herabstufung | CL King | Buy → Neutral |
2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
2017-12-08 | Eingeleitet | Citigroup | Buy |
2017-12-05 | Eingeleitet | JP Morgan | Overweight |
2017-11-13 | Eingeleitet | CL King | Buy |
2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
2017-07-21 | Eingeleitet | William Blair | Outperform |
2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Yousif Capital Management LLC Has $2.01 Million Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Does Repligen Corp (RGEN) Have a Strong Pricing Power? - Insider Monkey
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Parallel Advisors LLC Has $36,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen at William Blair Conference: Innovation Drives Growth By Investing.com - Investing.com Canada
Repligen at William Blair Conference: Innovation Drives Growth - Investing.com
Repligen Corp (RGEN) Stock Price Up 5% on Jun 3 - GuruFocus
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers - Yahoo Finance
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? - Yahoo Finance
Repligen Corp (RGEN) Trading Down 3.33% on May 30 - GuruFocus
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? - Yahoo Finance
Cetera Investment Advisers Has $436,000 Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp (RGEN) Stock Price Up 4.35% on May 27 - GuruFocus
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - The Manila Times
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report - TradingView
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges By Investing.com - Investing.com UK
Repligen Corporation to Present at William Blair Growth Conference - Yahoo Finance
Repligen at RBC Capital Markets: Strategic Growth Insights - Investing.com Australia
Insider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN) - GuruFocus
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Mercer Global Advisors Inc. ADV Sells 1,039 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Pioneering innovation in bioprocessing: Repligen’s growing impact in the area and symbiotic relationship with WWETB - Business Post
Why Repligen Corp Stock Might Make Sense If Bought Today - Stocksregister
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
Stifel Financial Corp Grows Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Things To Consider Before Buying Repligen Corp (NASDAQ: RGEN) - Stocksregister
Global Hollow Fiber Filtration Market Set to Witness - openPR.com
M&A activity dominates Q1, nearly 99% total med-tech deal value - BioWorld MedTech
Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com - Defense World
Investor’s Toolkit: Key Ratios for Assessing Repligen Corp (RGEN)’s Performance - DWinneX
Repligen Corporation to Present at Upcoming May Investor Conferences - Yahoo Finance
Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright - Defense World
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RG - GuruFocus
Repligen (RGEN) Maintains Buy Rating with $180 Price Target | RGEN Stock News - GuruFocus
Leerink Partnrs Has Pessimistic View of Repligen Q2 Earnings - Defense World
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare - Insider Monkey
There is no doubt that Repligen Corp (RGEN) ticks all the boxes. - Sete News
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’ - Insider Monkey
Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to “Outperform” - Defense World
BlackRock, Inc. Reduces Stake in Repligen Corp: An In-Depth Anal - GuruFocus
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) - Benzinga
Wolfe Research Upgrades Repligen Corp (RGEN) to an Outperform from a Peer perform - knoxdaily.com
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty - Yahoo Finance
Repligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock News - GuruFocus
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):